Edition:
United Kingdom

Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

13.21USD
18 Sep 2018
Change (% chg)

$0.51 (+4.02%)
Prev Close
$12.70
Open
$12.60
Day's High
$13.22
Day's Low
$12.23
Volume
165,980
Avg. Vol
192,617
52-wk High
$70.00
52-wk Low
$10.44

Latest Key Developments (Source: Significant Developments)

Prothena Sees $9 Mln-$13 Mln Restructuring Charges In Q2
Friday, 25 May 2018 

May 25 (Reuters) - Prothena Corporation PLC ::PROTHENA CORP SAYS $9 MILLION-$13 MILLION RESTRUCTURING CHARGES RELATED TO WORKFORCE REDUCTION EXPECTED TO BE INCURRED IN Q2 2018 - SEC FILING.  Full Article

Prothena Announces Reorganization To Focus Resources On Advancing Neuroscience Pipeline
Thursday, 24 May 2018 

May 24 (Reuters) - Prothena Corporation PLC ::PROTHENA ANNOUNCES REORGANIZATION TO FOCUS RESOURCES ON ADVANCING NEUROSCIENCE PIPELINE.PROTHENA CORPORATION PLC - INITIATED A REORGANIZATION TO ALIGN ITS RESOURCES ON ADVANCING ITS BROAD NEUROSCIENCE PIPELINE.PROTHENA CORPORATION PLC - FOLLOWING REORGANIZATION EXPECTS ITS WORKFORCE TO BE APPROXIMATELY 63 POSITIONS..PROTHENA CORPORATION PLC - COMPANY IS REVISING ITS FULL YEAR 2018 FINANCIAL GUIDANCE.PROTHENA CORPORATION PLC - EXPECTS 2018 NET CASH BURN FROM OPERATING & INVESTING ACTIVITIES TO BE $40 TO $50 MILLION.PROTHENA CORPORATION PLC - AS A RESULT OF DISCONTINUATION OF NEOD001 DEVELOPMENT PROGRAM, WILL REDUCE WORKFORCE BY ABOUT 57 PERCENT.PROTHENA - ESTIMATED 2018 NET LOSS INCLUDES $80 TO $85 MILLION OF OPERATING EXPENSES ASSOCIATED WITH NEOD001 AND REORGANIZATION.PROTHENA - REORGANIZATION INCLUDES ONGOING CLINICAL-STAGE PROGRAMS FOR PRX002/RG7935, PROPRIETARY PROGRAM PRX004 DISCOVERY-STAGE PIPELINE.PROTHENA - REORGANIZATION INCLUDES DISCOVERY-STAGE PIPELINE, 3 PROGRAMS BEING ADVANCED UNDER COLLABORATION WITH CELGENE.  Full Article

Prothena reports Q3 loss per share $1.37
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Prothena Corporation Plc ::Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports third quarter financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Prothena Corporation Plc :Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports Q4 loss per share $1.41
Tuesday, 14 Feb 2017 

Prothena Corporation Plc : Prothena Corporation Plc - Company expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million . Prothena reports fourth quarter and full year 2016 financial results, and provides financial guidance and research and development update . Q4 loss per share $1.41 . Q4 revenue $200,000 . Q4 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-1.12 -- Thomson Reuters I/B/E/S .Prothena Corporation Plc - Estimated 2017 net cash burn from operating, investing activities is primarily driven by estimated net loss of $177 to $191 million.  Full Article

Prothena Q4 loss per share $1.41
Tuesday, 14 Feb 2017 

Prothena Corporation Plc : Prothena corporation plc - expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million . Prothena reports fourth quarter and full year 2016 financial results, and provides financial guidance and research and development update . Q4 loss per share $1.41 . Q4 revenue $200,000 . Q4 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-1.12 -- Thomson Reuters I/B/E/S .Prothena corporation plc - estimated net loss of $177 to $191 million for fy.  Full Article

Prothena appoints Dr. Gene G. Kinney as CEO
Monday, 3 Oct 2016 

Prothena Corporation Plc : Prothena announces appointment of Dr. Gene G. Kinney as president, chief executive officer and director .Appointments come following passing of Prothena's co-founder, President and CEO, Dale B. Schenk.  Full Article

Prothena Corporation - CEO Dale B. Schenk, passed away
Friday, 30 Sep 2016 

Prothena Corporation Plc : Says Co-Founder, President and Chief Executive Officer, Dr. Dale B. Schenk, passed away .Says Board is meeting shortly regarding succession and an announcement will follow.  Full Article